logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

R/R indolent B-cell lymphoma: durable efficacy, low late-onset toxicity with IV copanlisib

7 additional patients achieved CR at 2-year follow-up.